Business Context and Reporting Period
This Form 8-K, dated December 13, 2021, reports on Landec Corporation (not Lifecore Biomedical, Inc., as noted in the metadata request). The filing details the completion of a material asset disposition on December 13, 2021. Landec Corporation and its wholly owned subsidiary, Curation Foods, Inc., sold the "Eat Smart" business (salad and cut vegetable operations) to Taylor Farms Retail, Inc.
Key Financial Metrics
- Transaction Value: $73.5 million in cash, subject to a post-closing net working capital adjustment.
- Debt Reduction: The Company utilized net proceeds to repay $67.9 million in borrowings under existing credit agreements.
- Assets Transferred: Manufacturing facilities in Bowling Green, Ohio, and Guadalupe, California; warehouses; equipment; inventory; accounts receivable/payable; and intellectual property.
- Retained Operations: Curation Foods retained its O Olive and Yucatan businesses and interests in BreatheWay. Landec retained its Lifecore Biomedical business.
Material Changes
The primary material change is the divestiture of the Eat Smart business, which alters the Company's operational footprint and asset base. The transaction resulted in an immediate reduction of debt obligations by approximately $67.9 million. A transition services agreement was executed, requiring the Sellers to provide services for up to six months post-closing in exchange for fees.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance or updated financial outlooks beyond the transaction details. Risks associated with the transaction are governed by customary representations, warranties, and indemnification provisions within the Asset Purchase Agreement. The agreement notes that representations were made as of the signing date and may change thereafter. Pro forma financial information is referenced in Exhibit 99.1 but not detailed in the text of this filing.
Investor Verification Checklist
- Verify the final purchase price after the post-closing net working capital adjustment.
- Review the Unaudited Pro Forma Condensed Consolidated Balance Sheet (Exhibit 99.1) to assess the impact on liquidity and leverage.
- Confirm the specific terms and duration of the transition services agreement and associated fees.
- Clarify the distinction between Landec Corporation and Lifecore Biomedical, Inc., as the filing pertains to Landec.